Skip to content

Daclatasvir Impurity 4

Daclatasvir Impurity 4

Product Description
CAT No.
ALN-D036026
CAS No.
1007882-23-6
Mol. F.
C36H44N6O4
Mol. Wt.
624.8
Stock
Please Inquire
Chemical Name : Di-tert-butyl 2,2′-([1,1′-biphenyl]-4,4′-diylbis(1H-imidazole-5,2-diyl))(2S,2’S)-bis(pyrrolidine-1-carboxylate)
Smiles : O=C(OC(C)(C)C)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C5=CN=C([C@@H]6CCCN6C(OC(C)(C)C)=O)N5)C=C4
Inchi : InChI=1S/C36H44N2O10/c1-35(2,3)47-33(43)37-19-7-9-27(37)31(41)45-21-29(39)25-15-11-23(12-16-25)24-13-17-26(18-14-24)30(40)22-46-32(42)28-10-8-20-38(28)34(44)48-36(4,5)6/h11-18,27-28H,7-10,19-22H2,1-6H3/t27-,28-/m0/s1

A validated stability-indicating reverse-phase high-performance liquid chromatography method for daclatasvir, identification and characterization of degradation products using LC-ESI-QTOF-MS

By Warghade, Snehal V.; Bothara, Kailash G.nFrom Asian Journal of Pharmaceutical and Clinical Research (2019), 12(5), 302-308

Development and validation of HPLC fluorescence and UPLC/DAD stability-indicating methods for determination of hepatitis C antiviral agent daclatasvir

By Kamal, Andra H.; Ismail, Nahla S.; Mabroijk, Mokhtar M.; Bebawy, Lories I.; Mekky, Mai A. – From Journal of AOAC International (2019), 102(4), 1125-1131

A stability-indicating UPLC method for the determination of potential impurities and its mass by a new QDa mass detector in daclatasvir drug used to treat hepatitis C infection

By Jagadabi, Varaprasad; Kumar, P. V. Nagendra; Mahesh, Kasthuri; Pamidi, Srinivasu; Ramaprasad, L. A.; Nagaraju, D. – From Journal of Chromatographic Science (2019), 57(1), 44-53

Request For Quotation